Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies
high throughput FastROCS screening of Tofacitinib using the proprietary STRATA database

Sygnature Discovery Adopts OpenEye’s Orion™ Platform to Strengthen Molecular Design Services

Sygnature Accelerates Customers’ Drug Discovery Timelines with Improved Hit Identification, Lead Optimisation Capabilities

Sygnature has adopted OpenEye’s Orion™ platform to power our computational efforts in molecular design drug discovery solutions.

On behalf of pharmaceutical and biotechnology companies globally, all of Sygnature’s Computer-Aided Drug Design team will benefit from the Orion™ platform’s large-scale capabilities: virtual high-throughput screening of billions of molecules, molecular dynamics simulations including binding free energy calculations, and quantum mechanics calculations.

In using Orion, our scientists now can easily leverage the power of hundreds of thousands of CPUs at Amazon Web Services, which will have a dramatic impact on both the quality and diversity of the hits generated for our customers’ projects, while accelerating those projects’ timelines and reducing project costs.

“Our mission at Sygnature is quite simple,” said Dr. Simon Hirst, CEO and Founder of Sygnature Discovery, “to enable success for our customers through world class science, and to help bring life-changing therapeutics through the challenging drug discovery process in order to help patients get the best medicines possible.

“That means employing the best technologies available to support our scientists in that quest, and we are very excited to see how the Orion platform will power more efficiency and new breakthroughs in our projects.”

Our use of the Orion platform provides cloud-based molecular and data visualization and analytics as well as facile access to the latest scientific methods, making it possible for us to unify and operate modeling tasks for the first time without leaving the cloud.

“Sygnature Discovery is using Orion exactly as we conceived: as a molecular design ecosystem of data visualization, communication and workflow tools in a robust, scalable cloud environment,” said Dr. Anthony Nicholls, CEO of OpenEye Scientific. 

“It is really gratifying to see Sygnature helping its clients identify more hits and optimize more leads using Orion’s industry-leading technology infrastructure and scientific methods.”

If you have any questions or would like to discuss our capabilities, we’d love to hear from you. You can get in touch by using any of the contact forms.

Latest News

View All

Sygnature collaborates with Japanese bio-venture company Epigeneron

Five Arrows invests in Sygnature Discovery

Sygnature Discovery expands into early CMC development

Sygnature gains ISO:27001 certification for information security

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.